SANTA CLARA (dpa-AFX) - Agilent Technologies Inc. (A) said that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer for treatment with KEYTRUDA or pembrolizumab.
The announcement marked the seventh cancer type for which PD-L1 IHC 22C3 pharmDx has gained approval in the U.S.
PD-L1 expression is a critical biomarker for response to anti-PD-1 therapies such as KEYTRUDA. The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability of pathologists to identify patients who may be eligible for treatment with KEYTRUDA, the company said in a statement.
KEYTRUDA, in combination with chemotherapy, is approved for patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA-approved test.
Copyright RTT News/dpa-AFX
© 2020 AFX News
